nav-left cat-right

Research: MegaSporeBiotic & MegaPre Enhance SCFA Production and Microbial Diversity

Research: MegaSporeBiotic & MegaPre Enhance SCFA Production and Microbial Diversity

A recent study published in The International Journal of Pharmaceutics: X shows that taking MegaPreTM together with MegaSporeBioticTM both increases microbial diversity in the gut and increases total SCFA (short chain fatty acid) production by 80-140%.

When testing MegaSporeBiotic alone (without MegaPre), there was a still significant (though less impressive) 24-70% increase in total SCFAs among donors. For this reason, it is highly recommended to take MegaPre in conjunction with MegaSporeBiotic.

SCFA’s such as butyrate, are important anti-inflammatory metabolites that maintain intestinal homeostasis, maintain a healthy gut lining, and support a healthy immune system.

Microbiome Labs (manufacturer of MegaSporeBiotic and MegaPre) has completed 14 clinical trials. Recently they purchased a microbiome research lab at California State University in Sacramento.

Microbiome Labs utilizes the SHIME®️  model in many of their studies, a unique scientifically validated, dynamic model of the complete gastrointestinal tract from the stomach to the colon, to study chemical, enzymatic, and microbial variables of the digestive tract in a controlled in vitro setting.

The SHIME model includes 5 reactors that simulate the stomach, small intestine, and the 3 regions of the large intestine: the ascending, transverse, and descending colon. Careful control of the environmental variables in each reactor allows studying the effects of a compound or finished product in each segment of the digestive tract as well as the gut microbiome over several weeks.

SHIME stands for the Simulator of the Human Intestinal Microbial Ecosystem.

Print Friendly, PDF & Email